We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Joint Program Established to Maximize Opportunities of Evolving PACS Technology

By HospiMedica International staff writers
Posted on 03 Oct 2011
Agfa HealthCare (Mortsel, Belgium) announced the launch of a new joint program with Barco (Kortrijk, Belgium) to refresh the diagnostic display systems that are running Impax picture archiving and communication systems (PACS) solutions. More...
The display refresh program will provide customers with access to the latest diagnostic display technology, to meet the demands of new trends in healthcare information technology (IT).

As PACS technology progresses, so does the technology used in diagnostic displays. Agfa HealthCare is committed to enabling its customers to take full advantage of advances and new applications. “Currently, most diagnostic imaging is still done on conventional monochrome liquid crystal displays [LCDs]. But with the explosive growth in image data, new ways to present the images must be found,” explained Al Dyer, imaging informatics global business manager for Agfa HealthCare. “This means more advanced image presentation techniques, including, for example, an increased use of color. To make sure our customers get the most from our PACS solutions, we want to support them in transitioning to the latest display technology. Diagnostic color displays allow customers to use Agfa HealthCare’s color-enabled PACS features and advanced visualization capabilities. Furthermore, they offer the flexibility and efficiency radiologists need to streamline their workflow and accelerate their clinical performance.”

The color displays also allow the reading of grayscale images, providing the same level of grayscale image quality as the conventional displays. In addition to enabling customers to make optimal use of the advanced PACS features and visualization applications, such as registration and fusion, nuclear medicine, cardiology and volume viewing, the program will support the optimal clinical performance of the healthcare enterprise’s PACS system, as customers will have access to a secure, online, enterprise-wide quality assurance service. Finally, the LCD upgrade opportunity in the program provides customers with both the latest technology and increased performance. “We are pleased that this program will enable us to better serve our existing customers,” commented Mr. Dyer. “Thanks to the embedded quality assurance service, our customers will enjoy higher system uptime and greater diagnostic confidence, while freeing up valuable IT resources.”

Related Links:

Agfa HealthCare
Barco





Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Hybrid Arch Device
Neo EDE
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.